Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04466501 · ClinicalTrials.gov registry record · NA
ACR | LAB Urine Analysis Test System Evaluation of Performance
A NA study, sponsored by Healthy.io.
- Completed
- Registry status
- NA
- Development phase
- 375
- Enrollment target
NCT04466501: Completed NA study, sponsored by Healthy.io.
NCT04466501 is a NA study that has completed, run by Healthy.io. The registered enrollment target is 375 participants, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (73% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT04466501, a NA study, has completed, sponsored by Healthy.io.
- COMPLETED
- Registry status
- NA
- Development phase
- 375 participants
- Enrollment target
Study Summary
The ACR LAB is a prescription-only, nurse- or clinician-conducted in vitro diagnostic (IVD) device. The test is for the qualitative and semi- quantitative detection of Albumin, Creatinine, and the Albumin-to- Creatinine Ratio. The device is composed of a kit and a smartphone application using an image recognition algorithm. The degree of agreement of the ACR \| LAB as compared to the comparator device will be tested. Urine samples will be tested by a separate professional user on each device.
Interventions
- DEVICE ACR LAB
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 375 participants |
| Start Date | 2019-06-30 |
| Est. Completion | 2019-09-30 |
| Phase | NA |
What the finished NCT04466501 record still lists
NCT04466501 is an interventional study that assigns participants to a tested intervention. The registered 375 participants enrollment target is mid-sized for trials with a published cap, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (73% lower).
The record links to 0 conditions, and to 1 intervention - of which ACR LAB is the first listed.
NCT04466501 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT04466501 about?
NCT04466501 is a clinical study titled "ACR | LAB Urine Analysis Test System Evaluation of Performance". The ACR LAB is a prescription-only, nurse- or clinician-conducted in vitro diagnostic (IVD) device. The test is for the qualitative and semi- quantitative detection of Albumin, Creatinine, and the Albumin-to- Creatinine Ratio. The device is composed of a kit and a smartphone application using an ima...
What is the current status of trial NCT04466501?
This trial is currently completed. It is a NA study. The enrollment target is 375 participants. The study started on 2019-06-30. Estimated completion is 2019-09-30.
What interventions are being tested in trial NCT04466501?
The interventions under investigation include: ACR LAB (DEVICE).
Who is sponsoring clinical trial NCT04466501?
This trial is sponsored by Healthy.io, which has 7 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT04466501's enrollment target sits among peer trials
375 276th of 2000 higher than 1,721 of 2,000 other NA trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other NA trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT03686124 · 375 participants · Phase 1
ACTengine® IMA203/IMA203CD8 as Monotherapy or in Combination With Nivolumab in Recurrent and/or Refractory Solid Tumors
- NCT04059172 · 375 participants · Early Phase 1
Efficacy of Combined Ibuprofen and Acetaminophen Therapy Versus Ibuprofen Alone Versus Placebo Alone for Pain Management
- NCT04134923 · 375 participants
Imaging Biomarkers in Preclinical and Symptomatic AD
- NCT04569747 · 375 participants · Phase 2
A Single Arm Phase II Study of ADjuvant Endocrine Therapy, Pertuzumab, and Trastuzumab for Patients With Anatomic Stage I Hormone Receptor-positive, HER2-positive Breast Cancer
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI